Table of contents

  • Brand Names
  • Chemistry
  • Pharmacologic Category
  • Mechanism of Action
  • Therapeutic Use
  • Pregnancy and Lactation Implications
  • Contraindications
  • Warnings and Precautions
  • Adverse Reactions
  • Genes that may be involved
  • Drug Interactions
  • Dosage
  • Pharmacokinetics and Pharmacodynamics
  • Special Considerations

Brand Names


Denmark: Ibaril; Finland: Ibaril; Germany: Topisolon; Luxembourg: Topicorte; Netherlands: Ibaril, Topicorte; Spain: Flubason.

North America

Canada: Desoximetasone, Topicort; USA: Desoximetasone, Topicort.

Latin America

Brazil: Esperson.

Drug combinations


Desoximetasone: C~22~H~29~FO~4~. Mw: 376.46. (1) Pregna-1,4-diene-3,20-dione, 9-fluoro-11,21-dihydroxy-16-methyl-, (11β,16α)-; (2) 9-Fluoro-11 β,21-dihydroxy-16α – methylpregna-1,4-diene-3,20-dione. CAS-382-67-2 (1975).

Pharmacologic Category

Skin and Mucous Membrane Agents; Anti-inflammatory Agents. Topical Corticosteroid. (ATC-Code: D07AC03; D07XC02).

Mechanism of action

A synthetic fluorinated corticosteroid. Stimulates the synthesis of enzymes needed to decrease inflammation, suppress mitotic activity, and cause vasoconstriction.

Therapeutic use

Relief of the inflammatory manifestations of corticosteroid-responsive dermatoses (e.g. seborrheic or atopic dermatitis, localized neurodermatitis, anogenital pruritus, psoriasis, late phase of allergic contact dermatitis, inflammatory phase of xerosis).

Pregnancy and lactiation implications

Topical desoximetasone is teratogenic in animals. In general, the use of large amounts, or prolonged use, of topical corticosteroids during pregnancy should be avoided.

Unlabeled use


Hypersensitivity to desoximetasone or any component of the formulation. Topical fungal infections. Tuberculosis of skin herpes simplex.

Warnings and precautions

Development of Kaposi’s sarcoma (case reports) with prolonged treatment with corticosteroids. Adverse systemic effects including Cushing’s syndrome, hyperglycemia, glycosuria, fluid and electrolyte changes, and reversible HPA axis suppression (particularly in younger children) may occur when used on large surface areas, for prolonged periods, or with an occlusive dressing. Chronic use of corticosteroids in children may interfere with growth and development. Infants and children may be more susceptible to adverse systemic effects. Children also are at greater risk of glucocorticoid insufficiency during and/or after withdrawal of treatment. Intracranial hypertension has occurred in children. For dermatologic use only. Occlusive dressings may be used for severe or resistant dermatoses. Avoid using occlusive dressings on weeping or exudative lesions, or in skin infection. Allergic contact dermatitis (may manifest as failure to heal). Irritation might occur. May cause atrophy of the epidermis and subcutaneous tissue, mostly in intertriginous (e.g. axilla, groin), flexor, and facial areas with prolonged use.



Legal Notice
Privacy Policy
Cookie Policy


Phone: +34-981-780505
Location: Sta Marta de, C. P. Babío, S/N, 15165 Bergondo, A Coruña

Copyright © 2023 WAGEM

Add to cart